BioSpace News Archive

Oak Hill Financial is a leading Canadian marketing and distribution firm, focused on IIROC retail brokerage networks, servicing both asset managers and public companies.

Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference.

Aytu BioPharma, Inc. announced today that Josh Disbrow, Chairman and Chief Executive Officer will present during two upcoming investor conferences in September: H. C. Wainwright 23rd Annual Global Investment Conference: On demand presentation available beginning Monday, September 13, 2021 at 7 a.m. ET.

Hancock Jaffe Laboratories, Inc. , today announced that it has entered into a definitive agreement with a fund managed by Perceptive Advisors to purchase $20 million of its common stock and pre-funded warrants in a registered direct offering priced at-the-market under Nasdaq rules.

Verseau Therapeutics, Inc. today announced the appointment of Karen Tubridy, Pharm.D. as Chief Development Officer.

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced two key executive appointments that bring industry-leading market growth and access experience to the company.

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines and the nonprofit Institute for Life Changing Medicines (ILCM), today announced a new collaboration to develop a new mRNA therapeutic (mRNA-3351) for Crigler-Najjar Syndrome Type 1 (CN-1), an ultra-rare disease.

Invectys Inc. today announced that Praveen Tyle, Ph.D., Invectys Inc. President and CEO will participate in the H.C, Wainwright 23rd Annual Global Investment Conference to be held virtually September 13-15, 2021.

Alpha Cognition Inc. (TSX-V: ACOG)(OTCQB:ACOGF)(“Alpha Cognition”, or the “Company”), is pleased to announce the U.S. Food and Drug Administration (“FDA”) has accepted its Investigational New Drug (IND) application for lead candidate, ALPHA-1062, to proceed with the pivotal clinical phase (the “Pivotal”) of the development program.

Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced the appointment of Marcin Kortylewski, Ph.D. as Senior Scientific Advisor of Duet Therapeutics.